Policy specialists PsychedelicsEUROPE and biopharma company, Mycotopia Therapies, are partnering to explore opportunities for psychedelic care on the continent.
Focused on psychedelic-assisted psychotherapy, Mycotopia Therapies is researching the compounds to assist with conditions such as PTSD, anxiety, depression, palliative care and serotonin syndrome.
Its new partnership with Brussels-based PsychedelicsEUROPE is aiming to accelerate Mycotopia’s research and develop new models of care under the regulatory framework for the medicinal use of psychedelics for mental health in the EU.
Europe’s psychedelic healthcare ecosystem is growing rapidly. The continent is seeing an increase in innovative research centres exploring psychedelics, NGOs, investment funds and private companies that are attracting capital and mainstream support.
There have been more progressive developments elsewhere in the world such as Canada which has recently seen the inclusion of psychedelics in its Special Access Programme (SAP) – which will allow patients access to this medicine under certain conditions. As well, the US FDA has given the first grant to investigate the use of psilocybin for treating smoking addiction.
The EU is still formulating policies for psychedelic substances and PsychedelicsEUROPE is working to accelerate the development of regulations that work for the patient through its relationships with medical professionals, academia, and private sector shareholders.
Secretary-general of PsychedelicsEUROPE, Viktor Chvatal, commented: “With ambitious regulatory initiatives, such as the Europe’s Beating Cancer Plan, or the Pharmaceutical Strategy for Europe, we need to make sure that more focus and funding will be dedicated to innovative mental health solutions, like medicinal use of psychedelics.
“In Europe, our goal is to raise awareness about existing best practices in other countries amongst the EU policy makers and regulators to speed up the process.”
CEO of Mycotopia Therapies, Ben Kaplan, said: “We are grateful to be able to have a role in advancing psychedelic therapy across Europe in a way that is consistent with sustainability principles while ensuring patient accessibility.
“We believe this partnership with PsychedelicsEUROPE will provide numerous opportunities to transform innovation into real treatments for patients across the EU and beyond.
“With that in mind, we look forward to collaborating with the rich academic and biomedical science community in the EU, as well as its world-class talent, to advance our commercialisation efforts on our psychedelic assets.”
“Mycotopia Therapies is continuing to work toward completing the acquisition of botanical psilocybin pioneer, Ei.Ventures. The transaction is moving forward as planned, and we look forward to providing shareholders with additional updates in the very near future.”
[activecampaign form=52]
